Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Akanksha Bakshi

Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles

Intellia Therapeutics Inc

Intellia Therapeutics Inc. (NASDAQ:NTLA) shares tumbled after the company said it had temporarily paused patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of its experimental CRISPR therapy, nexiguran ziclumeran (nex-z), following a serious liver-related adverse event in one participant.

The company described the pause as a precautionary step while it works with regulators and medical experts to assess the incident.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.